$4,174.80 travel Payment -- Allergan (AbbVie) to Dr. Angela Stewart
Allergan (AbbVie) pays $4,174.80 for travel and lodging to a Texas dermatologist
This page provides a detailed analysis of a $4,174.80 travel payment from Allergan (AbbVie) to Dr. Angela Stewart. Data is from the CMS Open Payments (Sunshine Act) database.
Payment Details
| Field | Value |
|---|---|
| Amount | $4,174.80 |
| Payment Type | travel |
| Payment Nature | Travel and Lodging |
| Pharmaceutical Company | Allergan (AbbVie) |
| Physician | Dr. Angela Stewart |
| NPI Number | 1748321949 |
| Physician Specialty | Dermatology |
| Location | Houston, TX |
| Date of Payment | 2025-10-15 |
| Related Drug/Device | Opdivo |
| Conflict Assessment | Moderate -- Worth Noting |
AI-Powered Analysis of This Payment
The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.
Allergan (AbbVie) made a $4.2K travel payment to Angela Stewart, a Dermatology specialist in Houston, TX. The payment was associated with Opdivo. The payment of $4,174.80 to Dr. Angela Stewart by Allergan (AbbVie) for travel and lodging related to Opdivo is a significant expense. This payment occurred on October 15, 2025, indicating a recent engagement between the pharmaceutical company and the healthcare provider. The payment was made to a dermatologist in Houston, TX, suggesting a focus on skin-related treatments or research.
Patient Guidance: What This Payment Means for You
If you are a patient, this payment may represent expenses incurred by your doctor for educational or research purposes related to medications. It is advisable to discuss any concerns about your treatment or your doctor's relationships with pharmaceutical companies directly with your physician. Always discuss your treatment options with your healthcare provider and ask about alternatives.
Payment Context: Is This Amount Normal?
Payments for travel and lodging can vary widely depending on the nature of the event, such as conferences or speaker engagements; this amount may be within the typical range for extensive travel or multi-day events in dermatology, but context is needed.
Regulatory Context: Sunshine Act Requirements
Physicians and teaching hospitals must report payments received from pharmaceutical and medical device manufacturers, including travel and lodging expenses, to the Centers for Medicare & Medicaid Services (CMS) under the Open Payments program.
Related Topics
This payment is related to the following healthcare transparency topics:
- pharmaceutical-payments
- physician-compensation
- travel-expenses
- dermatology
- allergan
- abbvie
- opdivo
Understanding travel Payments
Travel and lodging payments cover transportation and accommodation expenses for physicians attending conferences, advisory board meetings, or speaking engagements sponsored by pharmaceutical companies. These payments can be substantial, particularly for international travel or multi-day events.
Frequently Asked Questions About This Payment
What was this $4.2K payment for?
This was a travel payment of $4.2K from Allergan (AbbVie) to Angela Stewart, categorized as "Travel and Lodging". It was associated with Opdivo. The payment was reported under the Sunshine Act (CMS Open Payments).
Does Angela Stewart accept pharmaceutical money?
Yes, Angela Stewart received this $4.2K payment from Allergan (AbbVie). Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Angela Stewart's full payment history on the CMS Open Payments database or on this site.
Is it legal for doctors to accept pharma payments?
Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.
Should I be concerned about this travel payment?
A travel payment of $4.2K should be evaluated in context. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.
How do I talk to my doctor about pharma relationships?
You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.
What types of pharma payments are most concerning?
Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.
Does pharma money affect what my doctor prescribes?
Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.
How does this compare to other doctors in Dermatology?
To compare this payment against Dermatology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Dermatology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.
What does this payment reveal about Angela Stewart's relationship with Allergan (AbbVie)?
The payment amount is substantial for travel and lodging, warranting further investigation into the nature of the travel. This $4.2K travel payment is part of the transparency data reported under the Sunshine Act.
Is this payment amount typical for Dermatology?
The specific drug mentioned, Opdivo, is an immunotherapy used in cancer treatment, which may or may not align with dermatology.
What should patients do after learning about this payment?
If you are a patient, this payment may represent expenses incurred by your doctor for educational or research purposes related to medications. It is advisable to discuss any concerns about your treatment or your doctor's relationships with pharmaceutical companies directly with your physician.
What else should I know about this travel payment?
The payment date is in the future, which is unusual for CMS Open Payments data and may indicate a data entry error or a prospective payment.
Related Reports
Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.